SAN MATEO, Calif. — November 18, 2025 — RapidAI, the pioneer of deep clinical AI and global leader in enterprise imaging, today announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI solution designed to transform the acute assessment and longitudinal management of aortic disease.

RapidAI remains committed to advancing deep clinical AI—intelligent algorithms that go far beyond traditional triage to meaningfully support clinical decision-making. Designed to detect more diseases with greater accuracy, this next-generation AI can potentially reduce the cognitive burden for radiologists, inform acute treatment and transfer decisions, and enhance longitudinal patient management. By delivering tools that characterize, quantify, visualize, and track disease over time, RapidAI equips care teams with actionable, clinically adaptive intelligence across the full continuum of care.

Built on the Rapid Enterprise™ Platform, Rapid Aortic exemplifies RapidAI’s deep clinical AI approach. The solution not only provides deep clinical information powered by AI to help clinicians quickly and accurately identify more aortic aneurysms, dissections, and other anomalies, but also automatically generates critical measurements, produces automated 3D reconstructions of the entire aorta, and tracks anatomical changes over time. This enables radiologists to quickly assess the aorta with reduced cognitive burden and faster reading times, while allowing surgeons and clinicians to more effectively monitor patients longitudinally, supporting the earlier detection of changes that may require timely, potentially life-saving interventions.
Rapid Aortic represents a significant advancement for patients and clinicians alike, as it enables the analysis of all CT scans that include the aorta—including post-treatment and non-contrast studies—to potentially assist clinicians in identifying and tracking pathology from the aortic arch in the chest to the iliacs in the pelvis. Within moments, it produces guideline-based measurements, including six zonal maximums and eighteen landmark metrics, delivering consistent results without any inter-reader variation. Advanced visualizations and lab-quality imaging support confident pre-procedure planning for vascular and cardiothoracic surgeons. Built-in longitudinal comparisons enable tracking side by side with prior comparisons, and personalized notifications streamline follow-up and prevent missed progress. These automated, guideline-driven capabilities reduce variability, save time for radiologists and technologists, and strengthen multidisciplinary collaboration.

Products and Clearances Homepage